Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced for type 2 diabetes therapy nearly 10 years ago, among them short-acting compounds on the basis of the GLP-1-like peptide exendin-4 (exenatide and lixisenatide) and a long-acting GLP-1 RA based on the human GLP-1 sequence (lixisenatide). Recently, two novel long-acting GLP-1 RAs on the basis of human GLP-1 sequence, for once-weekly application, have been approved for therapy of type 2 diabetes. Additionally, liraglutide has been approved for treatment of obesity at a higher dose than that used for diabetes therapy. This mini-review gives a short overview of the novel long-acting GLP-1 RAs albiglutide and dulaglutide and also reviews the studies of liraglutide in treatment of obesity leading to its approval for this use. These studies were largely presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in fall 2014.

Keywords
Type 2 diabetes, obesity, GLP-1 receptor agonists, albiglutide, dulaglutide, liraglutide

Albiglutide
Albiglutide is a molecule consisting of two copies of a 30-amino acid sequence of a human GLP-1 dimer genetically fused to human albumin. Degradation is inhibited by a single amino acid substitution within the GLP-1 fragment. Additionally, the fusion to albumin results in a longer half-life. Maximum concentrations of albiglutide are reached 3 to 5 days after a subcutaneous dose, and steady-state concentrations are achieved after 4 to 5 weeks of once-weekly administration.

This review aims to give an overview of the recently published clinical study data on the novel long-acting GLP-1 RAs albiglutide and dulaglutide with a human GLP-1 ligand. In addition, recent data on the long-acting GLP-1 receptor agonist liraglutide, which also has a human GLP-1 sequence and is for treating obesity, are presented. Most of the clinical study data dealt with in this article were presented at the recent annual meeting of the European Association for the Study of Diabetes (EASD) in 2014. These data were also prerequisites for the approval of albiglutide and dulaglutide for the treatment of type 2 diabetes with once-weekly injections. The indication for liraglutide was widened to additionally include the treatment of morbid obesity without type 2 diabetes.
An HbA1c reduction of −0.55% to −0.9% was observed in these studies, and albiglutide was found superior to treatment using a sulphonylurea, pioglitazone or dipeptidyl peptidase-4 (DPP4) inhibitor. Non-inferiority was demonstrated versus insulin therapy. The mean body weight change was lower in comparison to other GLP-1 RAs, amounting to 0.3 to −1.2 kg, and was less when albiglutide was combined with oral anti-diabetics known to cause weight gain (pioglitazone, sulphonylurea).

The overall hypoglycaemia rates were low, similar to those of other GLP-1 RAs, when albiglutide was used as monotherapy or in combination with oral anti-diabetics known to cause weight gain (pioglitazone, sulphonylurea).

Table 1: Glycaemic Efficacy and Body Weight Changes in the Phase III Clinical Studies with Albiglutide (HARMONY Studies; summarised from references 8–16)

| Study (Reference) | Comparator and Treatment Arms (Number of Patients) | Duration (Weeks) | Baseline HbA1c (%) | Change in HbA1c (%) | Baseline Body Weight (kg) | Change in Body Weight (kg) | Patients Needing Rescue Therapy (%) |
|-------------------|----------------------------------------------------|------------------|--------------------|---------------------|--------------------------|--------------------------|-----------------------------------|
| HARMONY 1         | Reusch et al. 2014 9 ALB+PIO+MET (149)             | 52               | 8.1                | −0.81*              | 98                       | 0.3                      | 24.4*                             |
|                   | PBO+PIO+MET (150)                                    |                  | 8.1                | −0.05               | 100                      | 0.5                      | 47.7                              |
|                   | ALB dose 30 mg                                        |                  |                    |                     |                          |                          |                                   |
|                   | MET dose ≥1,500 mg                                    |                  |                    |                     |                          |                          |                                   |
|                   | PIO dose ≥30 mg                                       |                  |                    |                     |                          |                          |                                   |
| HARMONY 2         | Nauck et al. 2013 10 ALB 30 mg (100)                 | 52               | 8.1                | −0.7*               | 90                       | −0.7                     | 20                                |
|                   | ALB 50 mg (97)                                       |                  | 8.2                | −0.89*              | 90                       | −0.9                     | 16                                |
|                   | PBO (99)                                             |                  | 8.0                | 0.15                | 90                       | −0.7                     | 50                                |
| HARMONY 3         | Ahren et al. 2014 11 ALB+MET (297)                   | 104              | 8.1                | −0.63**             | 90                       | −1.2**                   | 25.8**                            |
|                   | SIT+MET (300)                                        |                  | 8.1                | −0.28               | 90                       | −0.9                     | 36.4                              |
|                   | GLM+MET (302)                                        |                  | 8.1                | −0.36               | 92                       | 1.2                      | 32.7                              |
|                   | PBO+MET (100)                                        |                  | 8.1                | 0.27                | 92                       | −1.0                     | 59.2                              |
| HARMONY 4         | Weissmann et al. 2014 12 ALB+MET±SU (496)            | 52               | 8.3                | −0.67†              | 95                       | −1.1                     | 25.6                              |
|                   | GLA+MET±SU (239)                                     |                  | 8.4                | −0.79               | 95                       | 1.6                      | 23.8                              |
| HARMONY 5         | Home et al. 2014 13 ALB+MET+GLM (269)                | 52               | 8.2                | −0.55**             | 91                       | −0.4**                   | n/a                               |
|                   | PIO+MET+GLM (273)                                    |                  | 8.3                | −0.80               | 91                       | 4.4                      |                                   |
|                   | PBO+MET+GLM (115)                                    |                  | 8.3                | 0.33                | 90                       | −0.4                     |                                   |
| HARMONY 6         | Rosenstock et al. 2014 14 ALB+GLA±OAD (282)          | 26               | 8.5                | −0.82               | 93                       | −0.7*                    | 22.9                              |
|                   | Lispro+GLA±OAD (281)                                 |                  | 8.4                | −0.66               | 92                       | 0.8                      | 24.4                              |
|                   | Baseline OADs allowed: PIO, MET, AGI                 |                  |                    |                     |                          |                          |                                   |
|                   | 68% MET only; 6% MET+PIO; 23% neither GLA titrated    |                  |                    |                     |                          |                          |                                   |
|                   | per protocol (mean 53.2 cU)                          |                  |                    |                     |                          |                          |                                   |
|                   | ALB 30–50 mg (51% on 50 mg)                           |                  |                    |                     |                          |                          |                                   |
|                   | Lispro adjusted per protocol (mean 50.6 cU)          |                  |                    |                     |                          |                          |                                   |
| HARMONY 7         | Pratley et al. 2014 15 ALB+≥1 OAD (402)              | 32               | 8.2                | −0.78†              | 92                       | −0.6                     | 15                                |
|                   | Lira+≥1 OAD (403)                                    |                  | 8.2                | −0.99               | 93                       | −2.2*                    | 8                                 |
|                   | Baseline OADs allowed: MET, TZD, SU                  |                  |                    |                     |                          |                          |                                   |
|                   | ~40% monotherapy, ~50% two drugs                     |                  |                    |                     |                          |                          |                                   |
|                   | ALB titrated to 50 mg                                |                  |                    |                     |                          |                          |                                   |
|                   | Lira titrated to 1.8 mg                              |                  |                    |                     |                          |                          |                                   |
| HARMONY 8         | Leiter et al. 2014 16 ALB+OAD (246)                  | 26               | 8.1                | −0.83               | 83.3                     | −0.79*                    | 6.1*                              |
|                   | SIT+OAD (240)                                        |                  | 8.2                | −0.52               | 82.8                     | −0.19                    | 12.1                              |
|                   | ALB 30–50 mg (mean 42.4 mg)                          |                  |                    |                     |                          |                          |                                   |
|                   | SIT dose based on renal function                     |                  |                    |                     |                          |                          |                                   |

AGI = alpha-glucosidase inhibitors; ALB = albiglutide; GLA = insulin glargine; GLM = glimepiride; Lira = liraglutide; MET = metformin; OAD = oral anti-diabetic agent; PIO = placebo; PIO = pioglitazone; SIT = sitagliptin; *ALB significant versus PBO; +ALB significant versus active comparator; **ALB significant versus GLM; †ALB significant versus SIT; ‡ALB non-inferior to active comparator; ††Non-inferiority of ALB versus active comparator not met; *Comparator significant versus ALB.
with metformin or pioglitazone. Higher rates were observed only in combination with a sulphonylurea or insulin. As expected when using a GLP-1 RA, the most commonly reported adverse events were gastrointestinal and occurred at a higher rate than with placebo, pioglitazone, sulphonylurea, a DPP-4 inhibitor or insulin, but less frequently than with liraglutide.8–16

The advantages of albiglutide include once-weekly dosing and fewer gastrointestinal side effects than the GLP-1 RA liraglutide, but it is less effective at reducing HbA1c and body weight than liraglutide.17,24 The incidence of

| Study (Reference) | Comparator and Treatment Arms | Duration (weeks) | Baseline HbA1c (%) | Change in HbA1c (%) | Baseline Body Weight (kg) | Change in Body Weight (kg) |
|-------------------|-------------------------------|-----------------|-------------------|--------------------|--------------------------|---------------------------|
| AWARD 1           | DU 0.75 mg+PIO+MET (263)      | 26              | 8.1               | −1.30§             | 96                       | 0.2                       |
|                   | DU 1.5 mg+PIO+MET (260)       |                 | 8.1               | −1.51**            | 96                       | −1.3                      |
|                   | EXE 100+PIO+MET (252)         |                 | 8.1               | −0.99*             | 97                       | −1.07                     |
|                   | PIO+PIO+MET (124)             |                 | 8.1               | −0.46              | 94                       | 1.24                      |
|                   | MET dose ≥1,500 mg            |                 |                   |                    |                          |                           |
|                   | PIO dose ≥30 mg               |                 |                   |                    |                          |                           |
| AWARD 2           | DU 0.75 mg (272)              | 52              | 8.1               | −0.76*             | 86.3                     | −1.33^                   |
|                   | DU 1.50 mg (273)              |                 | (average for all groups) | −1.08*             | (average for all groups) | −1.87*                   |
|                   | GLA (262)                     |                 | −0.63             | 1.44               |                          |                           |
|                   | MET dose ≥1,500 mg            |                 |                   |                    |                          |                           |
|                   | Average GLA dose ≥9 U         |                 |                   |                    |                          |                           |
| AWARD 3           | DU 0.75 mg (242)              | 26              | 7.6               | −0.71†             | 93                       | −1.36                     |
|                   | DU 1.50 mg (233)              |                 | 7.6               | −0.78*             | 92                       | −2.29                     |
|                   | GLA (226)                     |                 | 7.6               | −0.56              | 92                       | −2.22                     |
|                   | MET dose ≥1,500 mg            |                 |                   |                    |                          |                           |
| AWARD 4           | DU 0.75 mg (293)              | 26              | 8.5               | −1.59°             | 91.1                     | 0.18**                    |
|                   | DU 1.50 mg (295)              |                 | (average for all groups) | −1.64°             | (average for all groups) | −0.87**                   |
|                   | GLA (296)                     |                 | −1.41             | 2.33               |                          |                           |
|                   | MET dose ≥1,500 mg            |                 |                   |                    |                          |                           |
|                   | GLA dose titrated per protocol (mean 65 U) |           |                   |                    |                          |                           |
|                   | Lispro dose at endpoint: 97 U for DU 0.75 mg | | | | | |
|                   | 93 U for DU 1.5 mg | | | | | |
|                   | 68 U for GLA | | | | | |
| AWARD 5           | DU 0.75 mg+MET (268)          | 52              | 8.2               | −0.87              | 96                       | −2.60**                   |
|                   | DU 1.5 mg+MET (258)           |                 | 8.1               | −1.10‡             | 87                       | −3.03*                    |
|                   | SITA 100+MET (270)            |                 | 8.1               | −0.39              | 86                       | −1.53                     |
|                   | PIO+PIO+MET (124)             |                 | 8.1               | −0.87              | 87                       |                           |
|                   | MET dose ≥1,500 mg            |                 |                   |                    |                          |                           |
| AWARD 6           | DU 1.5 mg+MET (269)           | 26              | 8.1               | −1.42‡             | 93.8                     | −2.90                     |
|                   | Lira 1.8 mg+MET (269)         |                 | 8.1               | −1.36              | 94.4                     | −3.61†                    |
|                   | MET dose ≥2,000 mg            |                 |                   |                    |                          |                           |

DU = dulaglutide; GLA = insulin glargin; Lira = liraglutide; MET = metformin; PIO = placebo; PIO = pioglitazone; SIT = sitagliptin; *DU significant versus PIO; **DU superior versus active comparator; §DU significant versus GLA; DU noninferior to active comparator.

Table 2: Glycaemic Efficacy and Body Weight Changes in the Phase III Clinical Studies with Dulaglutide (AWARD Studies; summarized from references 18–24)

with liraglutide.17–24 The results from the AWARD studies 1–6 are published.17–24 An overview of the comparative clinical study programme with dulaglutide is given in Table 2.

The AWARD studies 7–9 are still ongoing, with results expected soon (AWARD 7: a study in patients with renal insufficiency dulaglutide vs. insulin glargin with insulin lispro in both study arms [ClinicalTrials.gov identifier: NCT01621178], AWARD 8: dulaglutide vs. placebo as add on to sulfonylurea [ClinicalTrials.gov identifier: NCT01769378], AWARD 9: dulaglutide vs. placebo as add on to metformin and insulin glargin [ClinicalTrials.gov identifier: NCT02152371]). In a direct comparison, the add -on of dulaglutide to patients failing on metformin was non-inferior compared with the addition of insulin glargine at the 0.75 mg dose and superior at the 1.5 mg dose.1 A direct head-to-head study comparing liraglutide with dulaglutide (in their respective maximal doses approved for type 2 diabetes therapy) showed non-inferiority for dulaglutide regarding the reduction of HbA1c and body weight.12–14 The incidence of
The long-acting GLP-1 RAs activate the GLP-1 receptor continuously, in contrast to the short-acting ones. The pharmacokinetic differences between these drugs lead to important differences in their pharmacodynamic profiles. The short-acting GLP-1 RAs mainly lower insulinotropic and glucagonostatic actions. The adverse effect profiles of these compounds also differ. The individual properties of the various GLP-1 RAs might allow incretin-based treatment of type 2 diabetes mellitus to be tailored to each patient’s needs. The once-weekly dosing of the novel GLP-1 RA may have beneficial effects beyond the glycaemic effects by direct action on the endocrine pancreas thanks to the widespread hypoglycaemic episodes and the adverse event profile was similar to other GLP-1 RAs.

**General Considerations about Long-acting GLP-1 Receptor Agonists**

The two novel long-acting GLP-1 RAs offer patients who have type 2 diabetes the advantage to lower the glycaemic parameters HbA1c and fasting and postprandial blood glucose while having a low risk of hypoglycaemia as well as the possibility of losing body weight. Generally, the gastrointestinal side effects (fullness and nausea) associated with GLP-1 RAs are less severe and less sustained than those of the short-acting GLP-1 RAs. Head-to-head studies between albiglutide and dulaglutide have not been performed so far. The percentage of patients reaching their glycaemic targets during therapy with GLP-1 RAs has been greater than that achieved with most established therapies for type 2 diabetes mellitus. Figures 1 and 2 show the changes in head-to-head studies with GLP-1 RA for HbA1c (see Figure 1) and body weight (see Figure 2).
expression of GLP-1 receptors. These may include cardiovascular effects, effects on lipid metabolism, neurological disorders and beneficial effects on saccadic blood pressure and body weight. These beneficial effects need to be counterweighed against possible side effects (e.g. gastrointestinal side effects, the increase of pulse rate observed with GLP-1 RA therapy). Data from the ongoing long-term safety studies are needed to judge whether the beneficial effects seen in preclinical and clinical trials will also improve long-term outcomes in the long run. Studies are also ongoing to elucidate the effects of GLP-1 RA in the treatment of type 1 diabetes in conjunction with insulin therapy, in which the effects of the GLP-1 RA on gastric emptying and glucagon secretion may have beneficial effects on glycemic control.25,26

**Liraglutide for the Treatment of Obesity**

A novel indication for the GLP-1 RA liraglutide is the treatment of obesity. Previous pivotal studies have already demonstrated a significant and sustained body weight reduction with liraglutide injected once daily at doses greater than the 1.2 mg and 1.8 mg used for diabetes.27 A large set of prospective clinical studies with more than 3,000 participants has subsequently investigated the effect of 3.0 mg liraglutide daily on the reduction of body weight, cardiovascular effects and safety. In this studies, liraglutide demonstrated a significantly better body weight reduction with 3.0 mg than with a 1.8 mg dose and with placebo. Indeed, 65 % of patients treated with the high dose of liraglutide lost more than 5 % of their body weight. In participants who had type 2 diabetes, the glycemic effects of both doses were comparable, whereas in study participants who did not have diabetes but who had prediabetes and obesity, the diabetes progression was retarded with use of the high dose of liraglutide. The reduction of blood pressure and the increase in pulse rate were comparable for both liraglutide doses. An improvement of cardiovascular surrogate risk markers was observed for C-reactive protein (CRP), for the lipid parameters and brain natriuretic peptide (BNP). Non-biochemical risk parameters, symptoms and scores for sleep apnoea also improved.

All effects of liraglutide were reversible, as observed after a 12-week washout phase at the end of the study.28-30

The most common side effect of the 3.0 mg dose of liraglutide was nausea (39 % versus 14 % in the 1.8 mg dose group) and other gastrointestinal side effects characteristic of the GLP-1 RA. Hypoglycemia was more frequent in the patients who had type 2 diabetes and concomitant sulphonylurea therapy, despite the reduction of the sulphonylurea dose by 50 % (15 % versus 6 %). During the study, seven cases of pancreatitis were observed in the liraglutide group and one case was detected in the placebo group. The incidence of gallstone complications was also higher in the liraglutide group (2.3 % versus 0.9 %).28-30

With the approval for the indication obesity for liraglutide, uses for GLP-1 RAs have widened beyond diabetes. The results from the cardiovascular safety and outcome studies lately performed with GLP-1 RA will also answer important questions about the effects of GLP-1 RA and body weight-lowering drugs on cardiovascular risk and on safety. The study results so far show that a higher dose of a GLP-1 RA seems to be safe in terms of fear about increased pulse rate and increased risk of pancreatitis. That progression of diabetes is decreased in subjects with prediabetes on treatment with liraglutide is an interesting finding deserving of more attention in further studies of type 2 diabetes prevention.